Spero Therapeutics (SPRO) Q2 2024 earnings summary

Executive summary

• Provided updates on clinical-stage assets SPR720, Tebipenem HBr, and SPR206, with a focus on rare diseases and multi-drug resistant bacterial infections.

• Announced the departure of Chief Medical Officer Kamal Hamed, with interim oversight by Dr. John C. Pottage, Jr.

• Net loss for Q2 2024 was $17.9 million, up from $11.9 million in Q2 2023; six-month net loss was $30.5 million.

• Cash and cash equivalents were $63.5 million as of June 30, 2024, expected to fund operations into late 2025.

• Revenue is derived from government contracts and collaboration agreements, with no product sales to date.

Financial highlights

• Q2 2024 revenue was $10.2 million, up from $2.7 million in Q2 2023, driven by collaboration and grant revenue.

• Research and development expenses rose to $23.7 million from $9.5 million year-over-year, mainly due to increased clinical trial activity.

• General and administrative expenses decreased to $5.5 million from $6.1 million year-over-year.

• Interest income for Q2 2024 was $1.2 million, including $0.4 million from the GSK License Agreement.

• Cash used in operations for the first half of 2024 was $12.8 million, down from $31.4 million in the prior year period.

Outlook and guidance

• Cash and non-dilutive funding expected to fund operations into late 2025; additional capital will be needed thereafter.

• Anticipates three remaining milestone payments from GSK, each approximately $24 million, every six months.

• Expects to share comprehensive SPR720 clinical data in Q4 2024 and Tebipenem HBr phase 3 enrollment completion in H2 2025.

• SPR206 Phase 2 trial initiation contingent on non-dilutive funding.

• If additional capital is not secured, spending reductions and program delays may occur.